Sugi Predict

Sugi Predict / Compounds / SCHEMBL4909757

SCHEMBL4909757

SCHEMBL4909757

FC(F)(F)c1ccc(-c2nc3c(Cl)ccnc3[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNB2 O95067 1/20 0.43
▸ CDK1 P06493 1/20 0.43
▸ CCNB1 P14635 1/20 0.43
▸ GSK3A P49840 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ CCNB3 Q8WWL7 1/20 0.43
▸ TNKS O95271 4/20 0.43
▸ TNKS2 Q9H2K2 4/20 0.43
▸ PARP1 P09874 2/20 0.43
▸ PARP2 Q9UGN5 2/20 0.43
▸ CBFB Q13951 1/20 0.42
▸ MAPK13 O15264 1/20 0.42
▸ RAF1 P04049 1/20 0.42
▸ MAPK12 P53778 1/20 0.42
▸ MAPK11 Q15759 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ GFER P55789 1/20 0.41
▸ WNT3A P56704 1/20 0.41
▸ SCN2A Q99250 2/20 0.40
▸ CXCR2 P25025 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909545 0.84 KDM4E (0.60) PARP1CBFBMAPK13RAF1MAPK12
SCHEMBL9692152 0.83 CCNB2 (0.46) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL3927381 0.83 TNKS (0.55) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL3919523 0.81 TNKS (0.47) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL3919893 0.79 PARP1 (0.50) GSK3AGSK3BTNKSTNKS2PARP1
SCHEMBL17645693 0.77 AURKA (0.63) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL4909647 0.76 KDM4E (0.47) CDK1GSK3AGSK3BPARP1MAPK13
SCHEMBL10742407 0.76 CCNB2 (0.51) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL30633310 0.75 HTT (0.39) PARP1CBFBTRPV1
SCHEMBL26686556 0.75 HTT (0.39) PARP1CBFBTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 — — US claimed
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 — — US disclosed
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 — — US disclosed
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders GSK3B, PYGB, GSK3A CCNB2 964/4885CDK1 27/4885CCNB1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.